- Wealth PMS
Deal flow for today shows FII leading the deal table. 2 US based funds Smallcap World Fund and Vanguard International Explorer Fund scored new deals worth 200 Crore by investing in Page Industries and Marksans Pharma.
Note: In Deal Flow, we summarize Bulk and Block Deals. A Bulk Deal is a trade where total quantity bought or sold is more than 0.5% of the number of equity shares of the company. A trade, with a minimum quantity of 5,00,000 shares or minimum value of Rs.5 crore executed through a single transaction on this separate window of the stock exchange will constitute a Block Deal.
Page Industries located in Bangalore, India are the exclusive licensees of JOCKEY International Inc. (USA) for manufacture and distribution of the JOCKEY® brand Innerwear/Leisurewear for Men and Women in India, Sri Lanka, Bangladesh ,Nepal and UAE. Page Industries is also the exclusive licensee of Speedo International Ltd. for the manufacture, marketing and distribution of the Speedo brand in India.
Smallcap World Fund – purchased 162,500 shares or 1.46% at an avg. price of Rs. 11,600/- per share making it one of their most expensive purchases of the recent times. This values the deal at Rs. 188 Crore.
Smallcap World Fund is one of few small-company growth funds that invests globally. Normally, at least 80% of assets will be invested in equities of issuers having market capitalizations of $4 billion or less, measured at time of purchase.
This deal resulted in a delivery volume of 96.57% (170,190 shares were delivered of 176,229 traded shares).
Here is the Shareholding Pattern in Page Industries for the period ended 31-Dec
Marksans Pharma, headquartered at Mumbai (India) is a global pharmaceutical company actively engaged in R&D and offer CRAMS to global pharmaceutical companies. Their key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others.
The plants are approved by prestigious US FDA, UK MHRA, Australian TGA and other foreign health authorities. The company possess end-to-end capabilities – from Lab scale development to Pilot scale up and from commercializing the product for large scale manufacturing to marketing globally.
Vanguard International Explorer Fund – the US based Mutual Fund made a huge buy of 2,366,133 shares or 0.58% at an avg. price of Rs. 50/- thereby valuing the deal at Rs. 11.8 Crore.
This deal resulted in a delivery volume of 32.18% (6,623,663 shares were delivered of 20,581,745 traded shares).
The company (Marksans Pharma) has been in the news recently:
Pursuant to the UK MHRA GMP inspection of the Marksans’s Goa plant conducted from November 23, 2015 to November 25, 2015 and subsequent to the Company’s response to the UK MHRA observations, the Company has received communication from UK MHRA informing that they are issuing a “Restricted GMP Certificate” allowing the Company to continue manufacture and marketing of critical products for the UK markets.
The restricted GMP status would continue until MHRA’s next inspection. Next re-inspection can be as early as when the Qualified Person EU (QP) certifies site to be inspection ready. Once re-inspected, the same can be reinstated to GMP compliant status.
As per MHRA’s assessment, listed products manufactured by Marksans Pharma for the UK market are evaluated to be critical for public health and are allowed continuation of manufacture. Marksans Pharma is committed to complete holistic remediation and be inspection ready to be GMP compliant at the earliest.
The Delhi based company is primarily engaged in the business of Project finance and investment.
Adihemshree Financial sold 121,000 shares or 1.21%. Part of this stake was purchased by Arihant Advertising.
Check out the Deal Flow for the other days:
Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.